Get the Stockscreener App
0.86
9.09%
0.0452
iBio Inc stock is traded at $0.86, with a volume of 335.80K.
It is up +9.09% in the last 24 hours and up +11.18% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$0.8148
Open:
$0.88
24h Volume:
335.80K
Relative Volume:
0.32
Market Cap:
$15.69M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.1297
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
-7.47%
1M Performance:
+11.18%
6M Performance:
-62.96%
1Y Performance:
-61.01%
1-Day Range:
$0.816
$0.93
1-Week Range:
$0.8113
$1.03
52-Week Range:
$0.6358
$6.8908
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.861 | 15.69M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.48 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio Extends Promissory Note Maturity to 2026 - TipRanks
Ibio nominates IBIO-610 as obesity development candidate - BioWorld MedTech
iBio initiates primate study for obesity antibody candidate IBIO-610 By Investing.com - Investing.com South Africa
iBio initiates primate study for obesity antibody candidate IBIO-610 - Investing.com
iBio (IBIO) Begins Preclinical Study of New Antibody Candidate | - GuruFocus
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | IBIO Stock News - GuruFocus
iBio initiates non-human primate study of IBIO-610 - TipRanks
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - The Manila Times
Breakthrough Obesity Drug Shows 77% Fat Reduction When Combined With GLP-1 Treatments - Stock Titan
iBio (IBIO) Plans to Offer 11.25 Million Shares of Common Stock - GuruFocus
Sector Update: Health Care - marketscreener.com
IBio Files Prospectus for Resale of About 11.3 Million Shares - marketscreener.com
Plant-Based Vaccines Market Future Business Opportunities 2025-2032 | Medicago, Inc., IBIO, Icon Genetics GmbH - newstrail.com
iBio: University of Limerick programme to ‘shape the next generation’ of pharmaceutical manufacturing experts - University of Limerick
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Plant-Based Vaccines Market Detailed In New Research Report - openPR.com
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World
Chardan Capital Has Bearish Outlook for iBio FY2025 Earnings - Defense World
Would I Consider iBio Inc (NASDAQ: IBIO) Stock Any Time In The Future? - Stocksregister
Balance Sheet Dive: iBio Inc (IBIO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO S - GuruFocus
iBio’s (IBIO) Buy Rating Reaffirmed at Chardan Capital - Defense World
iBio (NYSEMKT:IBIO) Shares Down 1.9% – Time to Sell? - Defense World
iBio announces new preclinical data for Activin E antibody - TipRanks
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Pri - GuruFocus
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Price Target | IBIO Stock News - GuruFocus
iBio (IBIO) Reports Promising Results from Activin E Antibody Study | IBIO Stock News - GuruFocus
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - The Manila Times
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat - GlobeNewswire
Revolutionary Obesity Treatment Achieves 77% Fat Reduction While Preserving Muscle Mass, Outperforms GLP-1s - Stock Titan
iBio, Inc. Reports Strong Q3 2025 Progress - TipRanks
iBio, Inc. (NYSE:IBIO) Shares Purchased by Geode Capital Management LLC - Defense World
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 20.9% in April - Defense World
IBio Reports Fiscal Third Quarter 2025 Financial Results - marketscreener.com
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline - GuruFocus
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results - The Manila Times
iBio, Inc. Reports Q3 2025 Financial Results and Corporate Progress Following Nasdaq Listing - Nasdaq
iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles - Stock Titan
Take off with iBio Inc (IBIO): Get ready for trading - Sete News
iBio Raises $6.2 Million Through Warrant Inducement Transaction - The Manila Times
Analyzing iBio Inc (IBIO) After Recent Trading Activity - knoxdaily.com
iBio Raises $6.2 Million Through Warrant Inducement Transaction | IBIO Stock News - GuruFocus
Biotech Firm iBio Raises $6.2M in Fresh Capital: New Warrants Issued at $0.86 - Stock Titan
What to expect from iBio Inc’s (IBIO) current quarter earnings? - uspostnews.com
Teck Resources Ltd [TECK] Insider Activity: An Update for Investors - knoxdaily.com
iBio (NYSE:IBIO) Trading Up 14.3% – Should You Buy? - Defense World
An Overview of iBio Inc (NASDAQ: IBIO)’s Stock Performance and Outlook - Marketing Sentinel
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):